SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-093327
Filing Date
2024-08-08
Accepted
2024-08-08 07:30:24
Documents
73
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q verv-20240630.htm   iXBRL 10-Q 2372260
2 EX-10.1 verv-ex10_1.htm EX-10.1 162602
3 EX-10.2 verv-ex10_2.htm EX-10.2 69166
4 EX-31.1 verv-ex31_1.htm EX-31.1 16264
5 EX-31.2 verv-ex31_2.htm EX-31.2 16353
6 EX-32.1 verv-ex32_1.htm EX-32.1 9059
7 EX-32.2 verv-ex32_2.htm EX-32.2 8983
  Complete submission text file 0000950170-24-093327.txt   8296617

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT verv-20240630.xsd EX-101.SCH 1161965
76 EXTRACTED XBRL INSTANCE DOCUMENT verv-20240630_htm.xml XML 1185604
Mailing Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 601 BOSTON MA 02215 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40489 | Film No.: 241186064
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)